THE U.S. Food and Drug
Administration (FDA) approved
Targiniq ER (oxycodone
hydrochloride and naloxone
hydrochloride extended-release
tablets), an extended-release/longacting
(ER/LA) opioid analgesic to
treat pain severe enough to require
daily, around-the-clock, long-term
opioid treatment.
It had properties which were
expected to deter but not fully
prevent abuse of drugs by snorting
and injection, the FDA said.
CLICK HERE for more.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.